Tuesday, December 3, 2019
4:00-5:00 p.m. Pre-Session
5:00-9:00 p.m. General Session
Wyndham Grand Hotel
*recently added* 4-5 CME Pre-Session:
Prevention, Diagnosis, and Treatment of HCV Infection PWID
5-9 General Session:
The Relationship Between the Abuse of Opioid Medications and Liver Disease CME Dinner Program
*recently added* CME Pre Session Program Overview:
Prevention, Diagnosis and Treatment of HCV Infection in PWID
Sponsored by ViralEd
Describe the epidemiology of and risk factors for the spread of HCV among PWID
Demonstrate improved knowledge and competence in terms of the current standards and guidelines for the diagnosis and management of PWID with chronic HCV
Apply data on treatment of HCV among PWID who are receiving opioid substitution therapy (OST) to their clinical setting
Describe the role of the addiction center in the team approach to treating chronic HCV infection in PWID
General Session Program Overview
The opioid epidemic has taken a toll individual lives, communities and our healthcare system and is an immediate healthcare emergency. The relationship between the abuse of opioid medications and liver disease is not understood among the provider population. Understanding and navigating effectively these off-setting circumstances will be critically important for providers and the community. The rising rates of opioid misuse coincide with a rise in viral hepatitis, particularly in young people, and in the increase in severity of liver disease across all age groups. Rates of hepatitis C (HCV), which can be spread between opioid users injecting drugs intravenously, are skyrocketing. HCV is 5 times as infectious as HIV, for example. Chronic HCV can lead to cirrhosis, liver cancer, transplant, and eventually death. It also puts patients at higher risk for developing other liver diseases, like fatty liver disease and nonalcoholic steatohepatitis. There is also a link between overdose deaths and the rise in available livers for transplantation. Harm reduction is more than a syringe service program and we need to mobilize to support our communities in the face of this Syndemic.
The goal of this course module is to help clinicians and other service providers understand the local and regional picture of addiction as it relates to liver health and diseases including, viral hepatitis, understand HCV screening recommendations, current treatment options, HIV/HCV coinfections, transplantation and organ donation implications, sexually transmitted diseases and specific issues with vulnerable populations especially and the opioid use disorder epidemic including adolescence, pregnant women and people who use drugs.
Who Should Attend
This program is directed to primary care physicians, specialists (ID, Gastro, Hepatology, Transplant, Addiction ), nurses, public health, Drug and Alcohol counselors, care coordinators, advocates and other allied health care workers involved in the healthcare of patients who have risk factors for Hepatitis C particularly people who use drugs.
At course completion, attendees should be able to:
Take an evidence-based approach to understanding substance use disorders and its affect on liver health.
Address addiction as a chronic medical illness and harmful drug use as a personal and public health problem in all contexts. Make referrals for specialty treatment of addiction and other medical and psychiatric conditions.
Obtain core medical knowledge about substance, substance use substance-related health conditions, and common co-occurring disorders.
Alcoholic Fatty Liver Disease
Wrap Up Panel
**Industry partners must have an exhibit to attend the program. You can purchase your exhibit registration via the button below or by contacting Suzanna Masartis at Suzanna@communityliveralliance.org.